The history of glucosamine and chondroitin: how a supplement became popular
Glucosamine and chondroitin have been staples of the joint-care aisle for a quarter of a century. Our editorial team traced their journey from chemistry laboratories to mass-market supplements, and how the evidence has evolved along the way.
Origins in nineteenth-century chemistry
Glucosamine was first prepared in 1876 by the German surgeon Georg Ledderhose, who isolated it by breaking down chitin, the tough material in the shells of crustaceans and insects. For decades it remained a laboratory curiosity of interest mainly to biochemists studying sugars and connective tissue.
Chondroitin sulphate has an equally academic origin. Scientists in the late nineteenth and early twentieth centuries identified it as a major component of cartilage, the smooth, rubbery tissue that covers the ends of bones in joints. It is a long chain of repeating sugar units that attracts water and gives cartilage its springy, shock-absorbing quality.
The logical link was tempting. If cartilage is made of these molecules, and osteoarthritis involves cartilage breakdown, then supplying them in the diet might help repair or protect joints. That reasoning, appealing but untested, set the stage for everything that followed.
In the mid-twentieth century, researchers in Europe, particularly in Italy, began studying glucosamine sulphate as a drug for osteoarthritis. By the 1980s, it was licensed as a prescription medicine in several European countries, while in other markets it was sold as a food supplement.
The leap to supermarket shelves
The real explosion in popularity came in the late 1990s. A best-selling book published in 1997, promising an "arthritis cure" based on glucosamine and chondroitin, brought the combination to a mass audience in North America and, soon after, Britain.
Its timing was ideal. Populations were ageing, interest in "natural" remedies was rising, and many people with joint pain were looking for alternatives to anti-inflammatory painkillers, which carry well-known risks for the stomach, kidneys and heart.
Sports and fitness culture soon adopted the products too. Runners, footballers and weightlifters began taking glucosamine to "protect" joints, often without any diagnosis of joint disease. Combination formulas added MSM, collagen, turmeric and fish oil.
By the early 2000s, glucosamine and chondroitin were among the best-selling supplements in the UK, with displays in supermarkets and high-street chemists.
The science catches up
Early trials, often small and frequently funded by manufacturers, reported encouraging results. A two-year trial by Reginster and colleagues in The Lancet found that patients taking glucosamine sulphate had less narrowing of the knee joint space on X-ray than those on placebo.
The landmark independent study was the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), funded by the US National Institutes of Health and published by Clegg and colleagues in 2006. Overall, neither glucosamine, chondroitin nor the combination significantly reduced knee pain compared with placebo. A possible benefit in a subgroup with moderate to severe pain was flagged, but it was not conclusive.
A network meta-analysis by Wandel and colleagues in the BMJ in 2010 pooled the large trials and concluded that, compared with placebo, glucosamine, chondroitin and their combination did not produce clinically relevant reductions in joint pain or narrowing of joint space.
| Year | Study | Headline finding |
|---|---|---|
| 2001 | Reginster et al., Lancet | Less joint space narrowing with glucosamine sulphate |
| 2006 | GAIT, NEJM | No overall pain benefit versus placebo |
| 2010 | Wandel et al., BMJ | No clinically relevant effect on pain or structure |
Debate continues over whether specific crystalline glucosamine sulphate preparations used in some European trials behave differently from the hydrochloride forms common in supplements, but the overall picture became much less rosy.
UK guidance and safety
In the UK, NICE guidance on osteoarthritis advises clinicians not to offer glucosamine for managing the condition. Glucosamine is no longer routinely prescribed on the NHS, though it remains widely available as a food supplement.
The recommended first-line treatments are less glamorous but better supported: exercise therapy to strengthen muscles around the joint, weight management where relevant, education and, when needed, appropriate pain relief.
- Glucosamine is often derived from shellfish; people with shellfish allergy should check the source.
- There have been reports of increased bleeding risk in people taking warfarin with glucosamine; anyone on anticoagulants should seek advice.
- People with diabetes may wish to monitor blood glucose when starting, though large effects appear unlikely.
- Safety in pregnancy and breastfeeding is not established.
For athletes without joint disease, there is no good evidence that these supplements prevent injury or cartilage damage. Load management, technique and strength training remain the mainstays of joint health.
Why the products remain popular
Despite disappointing trial results, glucosamine and chondroitin sales have remained substantial. Part of the explanation is the placebo response, which is notably strong in osteoarthritis pain trials. Many people genuinely feel better, even if the supplement itself is not the reason.
Osteoarthritis symptoms also fluctuate naturally. Starting a supplement during a flare and noticing improvement weeks later can create a convincing but misleading impression of benefit.
The products are relatively safe for most people, which lowers the perceived cost of trying them. For some, they offer a sense of doing something positive.
Our editorial view is that it is reasonable to try a reputable product for a fixed period, such as three months, and stop if there is no clear improvement. It should never replace exercise, physiotherapy or medical assessment of persistent joint pain.
Editorial conclusions
Glucosamine and chondroitin moved from nineteenth-century laboratories to European pharmacies and then to supermarket shelves, propelled by a simple and attractive idea.
High-quality independent trials and meta-analyses have not confirmed meaningful benefits for most people, and NICE does not recommend glucosamine for osteoarthritis.
Safety is generally acceptable, with specific cautions for shellfish allergy and anticoagulants.
Related topics on our site include collagen for joints, exercise therapy for knee osteoarthritis and how placebo effects shape supplement experiences.
References
- Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251–256.
- Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808.
- Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675.
- National Institute for Health and Care Excellence. Osteoarthritis in over 16s: diagnosis and management. NICE guideline NG226. London: NICE; 2022.
- Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;(2):CD002946.
- Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–1759.
